company background image
1530

3SBioSEHK:1530 Stock Report

Market Cap

HK$16.8b

7D

2.1%

1Y

-12.6%

Updated

30 Nov, 2021

Data

Company Financials +
1530 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance2/6
Financial Health6/6
Dividends0/6

1530 Stock Overview

3SBio Inc. researches, develops, manufactures, markets, and sells biopharmaceutical products in the People’s Republic of China.

Price History & Performance

Summary of all time highs, changes and price drops for 3SBio
Historical stock prices
Current Share PriceHK$6.67
52 Week HighHK$12.30
52 Week LowHK$6.16
Beta0.92
1 Month Change-6.32%
3 Month Change-22.44%
1 Year Change-12.58%
3 Year Change-44.69%
5 Year Change-14.49%
Change since IPO-28.66%

Recent News & Updates

Nov 21
An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

Does the November share price for 3SBio Inc. ( HKG:1530 ) reflect what it's really worth? Today, we will estimate the...

Sep 10
We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

1530HK BiotechsHK Market
7D2.1%-1.9%-3.0%
1Y-12.6%23.2%-5.2%

Return vs Industry: 1530 underperformed the Hong Kong Biotechs industry which returned 23.2% over the past year.

Return vs Market: 1530 underperformed the Hong Kong Market which returned -5.2% over the past year.

Price Volatility

Is 1530's price volatile compared to industry and market?
1530 volatility
1530 Average Weekly Movement4.9%
Biotechs Industry Average Movement7.9%
Market Average Movement6.8%
10% most volatile stocks in HK Market13.3%
10% least volatile stocks in HK Market3.3%

Stable Share Price: 1530 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 1530's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19935,232Jing Louhttps://www.3sbio.com

3SBio Inc. researches, develops, manufactures, markets, and sells biopharmaceutical products in the People’s Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis.

3SBio Fundamentals Summary

How do 3SBio's earnings and revenue compare to its market cap?
1530 fundamental statistics
Market CapCN¥13.78b
Earnings (TTM)CN¥1.03b
Revenue (TTM)CN¥6.00b

13.3x

P/E Ratio

2.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1530 income statement (TTM)
RevenueCN¥6.00b
Cost of RevenueCN¥1.10b
Gross ProfitCN¥4.89b
ExpensesCN¥3.86b
EarningsCN¥1.03b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.41
Gross Margin81.59%
Net Profit Margin17.20%
Debt/Equity Ratio18.4%

How did 1530 perform over the long term?

See historical performance and comparison

Valuation

Is 3SBio undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1530 (HK$6.67) is trading below our estimate of fair value (HK$13.46)

Significantly Below Fair Value: 1530 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1530's PE Ratio (13.3x) is in line with the Hong Kong Biotechs industry average.

PE vs Market: 1530 is poor value based on its PE Ratio (13.3x) compared to the Hong Kong market (9.3x).


Price to Earnings Growth Ratio

PEG Ratio: 1530 is poor value based on its PEG Ratio (1.7x)


Price to Book Ratio

PB vs Industry: 1530 is good value based on its PB Ratio (1.2x) compared to the HK Biotechs industry average (4.3x).


Future Growth

How is 3SBio forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

7.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1530's forecast earnings growth (7.7% per year) is above the savings rate (1.5%).

Earnings vs Market: 1530's earnings (7.7% per year) are forecast to grow slower than the Hong Kong market (17.7% per year).

High Growth Earnings: 1530's earnings are forecast to grow, but not significantly.

Revenue vs Market: 1530's revenue (7.6% per year) is forecast to grow slower than the Hong Kong market (12.5% per year).

High Growth Revenue: 1530's revenue (7.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1530's Return on Equity is forecast to be low in 3 years time (10.7%).


Past Performance

How has 3SBio performed over the past 5 years?

8.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1530 has high quality earnings.

Growing Profit Margin: 1530's current net profit margins (17.2%) are lower than last year (25.2%).


Past Earnings Growth Analysis

Earnings Trend: 1530's earnings have grown by 8.3% per year over the past 5 years.

Accelerating Growth: 1530's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1530 had negative earnings growth (-23.8%) over the past year, making it difficult to compare to the Biotechs industry average (51.1%).


Return on Equity

High ROE: 1530's Return on Equity (6.9%) is considered low.


Financial Health

How is 3SBio's financial position?


Financial Position Analysis

Short Term Liabilities: 1530's short term assets (CN¥7.4B) exceed its short term liabilities (CN¥1.3B).

Long Term Liabilities: 1530's short term assets (CN¥7.4B) exceed its long term liabilities (CN¥3.1B).


Debt to Equity History and Analysis

Debt Level: 1530 has more cash than its total debt.

Reducing Debt: 1530's debt to equity ratio has reduced from 57.6% to 18.4% over the past 5 years.

Debt Coverage: 1530's debt is well covered by operating cash flow (55.6%).

Interest Coverage: 1530 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is 3SBio current dividend yield, its reliability and sustainability?

0.091%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1530's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1530's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1530's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1530's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 1530 is not paying a notable dividend for the Hong Kong market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1530's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Jing Lou (58 yo)

no data

Tenure

CN¥3,904,000

Compensation

Dr. Jing Lou, M.D., Ph.D. is a Co-Founder of 3SBio Inc. and has been its Executive Chairman of the Board since April 1, 2012 and also serves as its Chief Executive Officer and President. Dr. Lou served as...


CEO Compensation Analysis

Compensation vs Market: Jing's total compensation ($USD611.20K) is about average for companies of similar size in the Hong Kong market ($USD527.57K).

Compensation vs Earnings: Jing's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 1530's management team is seasoned and experienced (5.6 years average tenure).


Board Members

Experienced Board: 1530's board of directors are considered experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

3SBio Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: 3SBio Inc.
  • Ticker: 1530
  • Exchange: SEHK
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$16.824b
  • Shares outstanding: 2.52b
  • Website: https://www.3sbio.com

Number of Employees


Location

  • 3SBio Inc.
  • No. 3 A1, Road 10
  • Shenyang Economy and Technology Developm
  • Shenyang
  • Liaoning Province
  • 110027
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/30 10:05
End of Day Share Price2021/11/30 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.